No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

The data thus far suggest fewer repeat interventions with the newly FDA approved resorbable device compared with PTA.

WASHINGTON, DC—For vascular closure after transfemoral TAVI, a strategy that combines suture- and plug-based devices halves ...

WASHINGTON, DC—How patients weigh the opinions of their family and friends when making decisions about PAD varies by sex and ...

Ami Bhatt and Michael Mack explore the ethics of AI use in the detection of subclinical cardiovascular disease.

Ami Bhatt and Michael Mack explain the economics of AI use in the detection of subclinical cardiovascular disease.

While discussions about the lack of a mortality effect will continue, some say the findings may be enough to change ...

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

The inability of QFR to rival FFR for 1-year MACE is a reminder of the need for large studies, even when new tech is enticing ...

With further refinement and defined thresholds for treatment, this technology has the potential to guide treatment decisions.

Select patients with moderate AS may benefit, but in general it’s okay to wait for severe stenosis, Nicolas Van Mieghem says.

The result calls into question the prospects of FDA approval for the Acurate neo2 valve, which is already in use globally.